Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGT-53 with Carboplatin and Pembrolizumab in Metastatic Triple Negative IBC
NCT05093387Phase 1Withdrawn
- Sponsor
- Northwestern University
- Start
- Nov 2022
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGT-53 in inflammatory breast cancer (IBC), sponsored by Northwestern University. Primary endpoints: Rate of Successful Administration up to 24 months and Clinical Benefit Rate. Planned start Nov 2022; status: withdrawn.
02
Drugs
SGT-53
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT05093387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093387.